Panorama_edited_sm.png

The Future of Gene Therapy

What does the future hold for gene therapy? Ben Brickell interviewed Jose F. Gomez and asked him about his career, his experience transitioning from Big Pharma to smaller biotech, and the current challenges facing the gene therapy industry.





Jose F. Gomez is a biotech global commercial leader with deep expertise in commercialization and market access of gene therapies (in vivo and ex vivo), orphan drugs and specialty pharmaceutical products. Jose has extensive experience in strategic marketing, patient access & value, new product planning, business development, and health policy. He successfully built and led global market access, reimbursement & value functions at several leading biopharma companies, including Avrobio, AveXis (now Novartis Gene Therapies), Shire, and Abbott.



Ben Brickell is the Director of the Venari Partners' Life Sciences & Healthcare practice. He works exclusively with emerging Biotech, MedTech and HealthTech companies across Europe and North America, and brings deep functional expertise from R&D through to Commercial. He can provide specialist support at every stage of his clients’ growth journey.